Furthermore, in combination with bevacizumab, an anti-VEGF monoclonal antibody, AMD3100 was tested in a Phase 1 study in patients with recurrent high-grade glioma (NCT01339039) showing that the combination was well tolerated, with a series of markers consistent with VEGF and CXCR4 inhibition [65]. The gene discussed is VEGFA; the disease is glioma.